Study to Assess the Effect of Macitentan on the Electroca... | NCT02050802

NCT02050802

Protocol Section

Identification Module

Results Section

No data available

No data is available for this block.

Annotation Section

No data available

No data is available for this block.

Document Section

No data available

No data is available for this block.

Derived Section

Miscellaneous Info Module

Status Module

Arms/Interventions Module

Arm Groups

Label	Type	Description	Intervention Names
Treatment sequence BCAD	Experimental	Subjects received study medication in the sequence BCAD. Treatment A: moxifloxacin positive control (3 placebo tablets once daily on Days 1-7, and on Day 8 moxifloxacin 400 mg tablet and 2 macitentan-matching placebo tablets). Treatment B: macitentan 10 mg (1 macitentan 10 mg tablet and 2 placebo tablets once daily on Days 1-8). Treatment C: macitentan 30 mg (3 macitentan 10 mg tablets once daily on Days 1-8). Treatment D: placebo (3 placebo tablets on Days 1-8). There was a wash-out period of at least 10 days between the last study drug administration of the previous treatment and the first study drug administration of the following treatment.	Drug: Moxifloxacin 400 mg Drug: Macitentan 10 mg Drug: Macitentan 30 mg Other: Placebo
Treatment sequence ABDC	Experimental	Subjects received study medication in the sequence ABDC. Treatment A: moxifloxacin positive control (3 placebo tablets once daily on Days 1-7, and on Day 8 moxifloxacin 400 mg tablet and 2 macitentan-matching placebo tablets). Treatment B: macitentan 10 mg (1 macitentan 10 mg tablet and 2 placebo tablets once daily on Days 1-8). Treatment C: macitentan 30 mg (3 macitentan 10 mg tablets once daily on Days 1-8). Treatment D: placebo (3 placebo tablets on Days 1-8). There was a wash-out period of at least 10 days between the last study drug administration of the previous treatment and the first study drug administration of the following treatment.	Drug: Moxifloxacin 400 mg Drug: Macitentan 10 mg Drug: Macitentan 30 mg Other: Placebo
Treatment sequence DACB	Experimental	Subjects received study medication in the sequence DACB. Treatment A: moxifloxacin positive control (3 placebo tablets once daily on Days 1-7, and on Day 8 moxifloxacin 400 mg tablet and 2 macitentan-matching placebo tablets). Treatment B: macitentan 10 mg (1 macitentan 10 mg tablet and 2 placebo tablets once daily on Days 1-8). Treatment C: macitentan 30 mg (3 macitentan 10 mg tablets once daily on Days 1-8). Treatment D: placebo (3 placebo tablets on Days 1-8). There was a wash-out period of at least 10 days between the last study drug administration of the previous treatment and the first study drug administration of the following treatment.

Interventions

Name	Type	Description	Arm Group Labels	Other Names
Moxifloxacin 400 mg	Drug		Treatment sequence ABDC Treatment sequence ADCB Treatment sequence BCAD Treatment sequence BCDA Treatment sequence CABD Treatment sequence CDBA

Outcomes Module

Primary Outcomes

Measure	Description	Time Frame
Baseline-adjusted placebo-corrected QT interval according to Fridericia's correction (QTcF)	The QTcF interval was obtained directly from the Holter ECG monitoring.Triplicate ECG recordings were obtained from a 12-lead Holter recording device at various time points on Day 8. Baseline data were obtained from the pre-dose recording on Day 1 (from about 45 to 15 minutes prior to the morning dose). The QTcF interval is the QT interval (interval from beginning of the Q wave until end of the T wave) corrected for heart rate with Fridericia's formula (QTcF = QT/RR^0.33 where RR is 60/heart rate)	Day 8

Secondary Outcomes

Measure	Description	Time Frame
Placebo corrected change from baseline in heart rate on Day 8	Heart rate was obtained directly from the Holter ECG monitoring. Triplicate ECG recordings were obtained from a 12-lead Holter recording device at various time points on Day 8. Baseline data were obtained from the pre-dose recording on Day 1 (from about 45 to 15 minutes prior to the morning dose).	Day 8

Eligibility Module

Eligibility Criteria

Inclusion Criteria:

Ability to communicate well with the investigator in the local language, and to understand and comply with the requirements of the study.
Signed and dated written informed consent prior to admission to the study in accordance with Good Clinical Practice and the local legislation.
Males and females aged ≥ 18 and ≤ 55 years at screening.
Women of childbearing potential must have had a negative pre-treatment serum pregnancy test and used consistently and correctly 2 methods of contraception at the same time from screening and up to 30 days after study treatment discontinuation. Abstinence was not considered a reliable method of contraception.
Healthy on the basis of medical history and the assessments performed at screening.
Physical examination without clinically relevant abnormalities at screening.
Body mass index (BMI) ≥ 18.0 and ≤ 28.0 kg/m^2 at screening. Body weight at least 50.0 kg.
Negative results from urine drug screen and alcohol test at screening.
Willing and able to refrain from alcohol consumption from study start to the end of the study.
Negative human immunodeficiency virus (HIV) serology and hepatitis serology at screening.
Systolic blood pressure (SBP) 100-145 mmHg, diastolic blood pressure (DBP) 50-90 mmHg, and heart rate (HR) 45-90 bpm (all inclusive), measured on the dominant arm (dominant arm = writing arm).
12-lead ECG without clinically relevant abnormalities at screening and on Day 1 prior to drug administration.
Hematology, blood chemistry, and urinalysis results not deviating from the normal range to a clinically relevant extent at screening and on Day 1 prior to drug administration.

Exclusion Criteria:

Known hypersensitivity to any excipients of the drug formulations.
Treatment with macitentan or another investigational drug in the 3 months prior to screening.
History or clinical evidence of any disease and/or the existence of any surgical or medical condition, which might have interfered with the absorption, distribution, metabolism, or excretion of macitentan and moxifloxacin (except appendectomy and herniotomy).
History or clinical evidence of drug abuse, alcoholism, or psychiatric disease within the 3 year period prior to screening.
Caffeine consumption ≥ 800 mg per day at screening.
History of fainting, collapse, syncope, blackouts, orthostatic hypotension, or vasovagal reactions.
Chronic or relevant acute infections.
History of relevant allergy/hypersensitivity.
Previous treatment with any prescribed or over-the-counter medications or herbal remedies (including herbal medicines such as St John's Wort) within 2 weeks prior to first dosing or during the trial.
Smoking and use of tobacco substitutes or nicotine substitutes.
Loss of 250 mL or more blood in the 3 months prior to dosing (including blood donation).
Positive results from the hepatitis serology at screening, except for vaccinated subjects.
Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) above the upper limit of normal prior to randomization.
Excessive physical activities within 1 week prior to randomization.
Any cardiac condition (including ECG abnormalities) or illness with a potential to increase the cardiac risk of the subject or that might affect the corrected QT analysis (QTc).
QTc > 450 ms or > 470 ms (using the ECG machine heart rate-correction method) before randomization for male or female subjects, respectively.
Subjects with personal or family history of long-QT syndrome or hypokalemia.
Legal incapacity or limited legal capacity at screening.
Veins unsuitable for intravenous (i.v.) puncture on either arm (e.g., veins that are difficult to locate, access or puncture; veins with a tendency to rupture during or after puncture).
Vulnerable subjects (e.g., persons kept in detention).
Employee of the investigator or study center, with direct involvement in the proposed study or other studies under the direction of that investigator or study center, as well as family members of the employees or the investigator.

ID	Term
D000077266	Moxifloxacin
C533860	macitentan

ID	Term
D024841	Fluoroquinolones
D042462	4-Quinolones
D015363	Quinolones
D011804	Quinolines